Trial results

$IMRX — atebimetinib

Immuneering Corp (IMRX) atebimetinib: trial results in First-line pancreatic cancer (PDAC), 2027.

Research by Catalyst Intel

The catalyst

"The Company plans to share further data from the mGnP arm of its Phase 2 PDAC trial (N = 55) in 1H 2027."

— Immuneering Corporation, 8-K filed 2026-10-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

IMRX-ATEBIMETINIB-2026

Company

Immuneering Corp

Kind

Trial results

Indication

First-line pancreatic cancer (PDAC)

Window

2027-01-01 – 2027-06-30

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-07-30; subscribers get it on the day.